Source: DGNews | Posted 9 years ago
Bexxar (Tositumomab/Iodine I 131 Tositumomab) Receives Strong Support From FDA Advisory Panel
Tags:
ODAC Panel Agrees That Bexxar Studies Show Clinical Benefit in Chemotherapy-and Rituximab-Refractory Low-grade, Transformed Low-grade NHL
SEATTLE, WA and PHILADELPHIA, PA -- December 18, 2002 -- Corixa Corporation (Nasdaq: CRXA) and GlaxoSmithKline (NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) agreed that studies of the investigational radioimmunotherapy Bexxar
Comments